Acute myeloid leukemiaTargeted therapyFLT3 inhibitorsBCL2 inhibitorsIDH inhibitorsHypomethylating agentsThe extensive genomic characterization of acute myeloid leukemia (AML) led to the identification of a vast number of potential therapeutic targets. We review relevant data that have led to recent approval...
Acute myeloid leukemia (AML) also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia.
New treatments for acute myeloid leukemia: how much has changed?doi:10.1038/s41375-020-01084-2Elihu EsteyLeukemia
Acute myeloid leukemia (AML) is a type of blood cancer.Learn about this cancer that forms in the bone and bone marrow. Treatments include medications and bone marrow transplant.
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival for younger patients over the last several decades has improved nearly sixfold with the optimization of intensive induction chemotherapy and allogeneic stem cell transplantation (alloHSCT), this effect has been ...
“Oncogenic fusions are often disease-defining and present a unique marker of leukemic cells that are not usually present in healthy cells. Other diseases such as chronic myeloid leukemia (CML) can already be tracked by the canonical BCR-ABL fusion and sensitively detecting these fusions has ...
Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow It occurs when the bone marrow, which is responsible for producing blood cells, starts making too many abnormal white blood cells called myeloblasts.
Traditionally, most acute myeloid leukemia (AML) subtypes have been distinguished from myelodysplastic syndrome (MDS) by the presence of at least 20% blasts in the bone marrow or peripheral blood, and for that reason, patients with blast levels that are elevated but less than 20% would typically...
Acute myeloid leukemia (AML) is the most frequent form of leukemia in adults. The disease develops very rapidly, and has a very poor prognosis, with an average overall 5-year survival rate of 29% with standard therapy. Immunotherapy has led to significant advances in the treatment of several...
"We're now also interested in finding out what other cancers outside of AML/MDS might benefit from this new activity of the drug," he said. Myelodysplastic syndrome changes into acute myeloid leukemia in approximately 30% of people and in Australia around 900 people are diagnosed with AML eac...